GGrantIndex
← Leaderboards

Luisa M Rodriguez

Baylor College Of Medicine

Google Scholar ↗PubMed ↗ORCID ↗
$1,009,706
Attributed
$1,009,706
Total exposure
18
Grants
18
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $231.8K · FY2006–13
$250K$187.5K$125K$62.5K$0
'06
'07
'08
'09
'10
'11
'12
'13

Funding mix

By agency

NIH$1,009,706 · 18

By mechanism

K23$693,083 · 1
M01$172,690 · 16
R03$143,933 · 1

Top collaborators

No co-investigators on record.

Most similar at Baylor College Of Medicine

Same institution · by research overlap

Others in their field

Top investigators on “Child”

Research focus

ChildGlucoseGlucagonFundingInsulinUnited States National Institutes Of HealthResourcesSourceGrantResearch PersonnelHyperglycemiaGlucagon-Like Peptide 1Diabetes MellitusGlycemic ControlChildhoodIslet Amyloid PolypeptideAnalogIncidenceMetabolicBlood Glucose RegulationGastric EmptyingHormonesNon-Insulin-Dependent Diabetes MellitusComputer Retrieval Of Information On Scientific Projects Database

Grant awards (23)

Glucose lowering effect of metformin and sitagliptin in adolescents with Type 1$70,701
R03 · FY2013 · DK · contact PI
Glucose lowering effect of metformin and sitagliptin in adolescents with Type 1$73,232
R03 · FY2012 · DK · contact PI
The role of amylin and GLP-1 mimetics in the treatment of children with T2DM$172,474
K23 · FY2011 · DK · contact PI
EXENATIDE (BYETTA) VS PRAMLINTIDE (SYMLIN)$31,661
M01 · FY2011 · RR · contact PI
THE EFFECT OF THE GLUCAGON SUPPRESSORS PRAMLINTIDE AND EXENATIDE ON POSTPRANDIAL$14,247
M01 · FY2011 · RR · contact PI
THE ROLE OF AMYLIN AND INCRETINS ON POSTPRANDIAL METABOLISMS IN ADOLESCENTS W$10,290
M01 · FY2011 · RR · contact PI
TYPE I DIABETES GENETIC CONSORTIUM (NORTH AMERICAN REGIONAL NETWORK)$1,583
M01 · FY2011 · RR · contact PI
EFFECTS OF GROWTH HORMONE THERAPY ON GLUCOSE AND PROTEIN METABOLISM IN CHILDR$1,583
M01 · FY2011 · RR · contact PI
The role of amylin and GLP-1 mimetics in the treatment of children with T2DM$172,627
K23 · FY2010 · DK · contact PI
TYPE I DIABETES GENETIC CONSORTIUM (NORTH AMERICAN REGIONAL NETWORK)$16,404
M01 · FY2010 · RR · contact PI
EFFECTS OF GROWTH HORMONE THERAPY ON GLUCOSE AND PROTEIN METABOLISM IN CHILDR$6,867
M01 · FY2010 · RR · contact PI
THE ROLE OF AMYLIN AND INCRETINS ON POSTPRANDIAL METABOLISMS IN ADOLESCENTS W$6,104
M01 · FY2010 · RR · contact PI
THE EFFECT OF THE GLUCAGON SUPPRESSORS PRAMLINTIDE AND EXENATIDE ON POSTPRANDIAL$4,578
M01 · FY2010 · RR · contact PI
The role of amylin and GLP-1 mimetics in the treatment of children with T2DM$173,391
K23 · FY2009 · DK · contact PI
EFFECTS OF GROWTH HORMONE THERAPY ON GLUCOSE AND PROTEIN METABOLISM IN CHILDR$10,369
M01 · FY2009 · RR · contact PI
TYPE 1 DIABETES GENETIC CONSORTIUM (NORTH AMERICAN REGIONAL) NETWORK)$4,444
M01 · FY2009 · RR · contact PI
The role of amylin and GLP-1 mimetics in the treatment of children with T2DM$1,080
K23 · FY2009 · DK · contact PI
THE ROLE OF AMYLIN AND INCRETINS ON POSTPRANDIAL METABOLISMS IN ADOLESCENTS W$889
M01 · FY2009 · RR · contact PI
The role of amylin and GLP-1 mimetics in the treatment of children with T2DM$173,511
K23 · FY2008 · DK · contact PI
THE ROLE OF AMYLIN AND INCRETINS ON POSTPRANDIAL METABOLISMS IN ADOLESCENTS W$7,808
M01 · FY2008 · RR · contact PI
EFFECTS OF GROWTH HORMONE THERAPY ON GLUCOSE AND PROTEIN METABOLISM IN CHILDR$7,139
M01 · FY2008 · RR · contact PI
THE ROLE OF AMYLIN AND INCRETINS ON POSTPRANDIAL METABOLISMS IN ADOLESCENTS W$46,863
M01 · FY2007 · RR · contact PI
THE ROLE OF AMYLIN AND INCRETINS ON POSTPRANDIAL METABOLISMS IN ADOLESCENTS W$1,861
M01 · FY2006 · RR · contact PI